Sanofi’s Berger On Creating A Sleek R&D Engine Fit For Purpose In The 2020s
A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track.
You may also be interested in...
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.